Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase III trial compares the effect of adding pirtobrutinib to the usual treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) to R-CHOP alone for the treatment of Richter transformation, which is when chronic lymphocytic leukemia or small lymphocytic lymphoma turns into large B-cell lymphoma, a more aggressive (faster-growing) form of lymphoma. Pirtobrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the body's immune response. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Adding pirtobrutinib to R-CHOP may kill more cancer cells than R-CHOP alone in patients with Richter transformation.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona diagnoza transformacji Richtera (przejście z przewlekłej białaczki limfocytowej na bardziej agresywny chłoniaka)
- •Mierzalne ślady nowotworu widoczne w badaniach obrazowych lub laboratoryjnych wykonanych w ciągu ostatnich 6 tygodni
- •Wykonane badanie PET/CT do oceny zaawansowania nowotworu w ciągu ostatnich 6 tygodni
- •Możliwość wcześniejszego leczenia białaczki, ale bez stosowania pirtobrutinibu
- •Wcześniejsze krótkie leczenie sterydami dopuszczalne (do 700 mg prednizonу łącznie, krócej niż 7 dni)
- •Brak przekroczenia bezpiecznej dawki poprzednich leków (doksyrubicyny) dla serca
✗ Disqualifies
- •Wcześniejsze leczenie transformacji Richtera innymi lekami niż sterydy
- •Przyjmowanie leków silnie wchodzących w interakcje z pirtobrutinibem (ostatnia dawka musi być co najmniej 7 dni przed badaniem)
- •Chemioterapia lub terapia anty-CD20 w ciągu ostatnich 2 tygodni przed włączeniem do badania
- •Przekroczona maksymalna kumulacyjna dawka doksyrubicyny (100 mg/m² dla R-CHOP lub 250 mg/m² dla R-mini-CHOP)
- •Bezwzględne przeciwwskazania do stosowania antracyklin (leki uszkadzające DNA komórek nowotworowych)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (62)
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, United States
UCI Health Laguna Hills
Laguna Hills, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, United States
Illinois CancerCare-Bloomington
Bloomington, United States
Illinois CancerCare-Canton
Canton, United States
Illinois CancerCare-Carthage
Carthage, United States
Carle at The Riverfront
Danville, United States
Cancer Care Specialists of Illinois - Decatur
Decatur, United States
Decatur Memorial Hospital
Decatur, United States
Carle Physician Group-Effingham
Effingham, United States
Illinois CancerCare-Eureka
Eureka, United States
Illinois CancerCare-Galesburg
Galesburg, United States
Illinois CancerCare-Kewanee Clinic
Kewanee, United States
Illinois CancerCare-Macomb
Macomb, United States
Carle Physician Group-Mattoon/Charleston
Mattoon, United States
Carle BroMenn Medical Center
Normal, United States
Carle Cancer Institute Normal
Normal, United States
Cancer Care Center of O'Fallon
O'Fallon, United States
HSHS Saint Elizabeth's Hospital
O'Fallon, United States
Illinois CancerCare-Ottawa Clinic
Ottawa, United States
Illinois CancerCare-Pekin
Pekin, United States
Illinois CancerCare-Peoria
Peoria, United States
Illinois CancerCare-Peru
Peru, United States
Illinois CancerCare-Princeton
Princeton, United States
Memorial Hospital East
Shiloh, United States
Southern Illinois University School of Medicine
Springfield, United States
Springfield Clinic
Springfield, United States
Springfield Memorial Hospital
Springfield, United States
Carle Cancer Center
Urbana, United States
Illinois CancerCare - Washington
Washington, United States
Our Lady of the Lake Physician Group
Baton Rouge, United States
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton, United States
Trinity Health IHA Medical Group Hematology Oncology - Canton
Canton, United States
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea, United States
Trinity Health Saint Mary Mercy Livonia Hospital
Livonia, United States
Trinity Health Saint Joseph Mercy Oakland Hospital
Pontiac, United States
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Ypsilanti, United States
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, United States
Siteman Cancer Center at West County Hospital
Creve Coeur, United States
Washington University School of Medicine
St Louis, United States
Siteman Cancer Center-South County
St Louis, United States
Siteman Cancer Center at Christian Hospital
St Louis, United States
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, United States
Duke University Medical Center
Durham, United States
Thomas Jefferson University Hospital
Philadelphia, United States
Huntsman Cancer Institute/University of Utah
Salt Lake City, United States
VCU Massey Cancer Center at Stony Point
Richmond, United States
VCU Massey Comprehensive Cancer Center
Richmond, United States
FHCC Overlake
Bellevue, United States
FHCC at EvergreenHealth
Kirkland, United States
Fred Hutchinson Cancer Center
Seattle, United States
FHCC at Northwest Hospital
Seattle, United States
University of Washington Medical Center - Montlake
Seattle, United States
Froedtert Menomonee Falls Hospital
Menomonee Falls, United States
Medical College of Wisconsin
Milwaukee, United States
ProHealth D N Greenwald Center
Mukwonago, United States
Froedtert and MCW Moorland Reserve Health Center
New Berlin, United States
Drexel Town Square Health Center
Oak Creek, United States
ProHealth Oconomowoc Memorial Hospital
Oconomowoc, United States
ProHealth Waukesha Memorial Hospital
Waukesha, United States
UW Cancer Center at ProHealth Care
Waukesha, United States
Froedtert West Bend Hospital/Kraemer Cancer Center
West Bend, United States
Trial contact
Site Public Contact
Catherine C. Coombs
PRINCIPAL_INVESTIGATOR
Site Public Contact
Bryan A. Faller
PRINCIPAL_INVESTIGATOR
Site Public Contact
Suparna Mantha
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Dilan A. Patel
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Nakhle S. Saba
PRINCIPAL_INVESTIGATOR
Site Public Contact
Tareq Al baghdadi
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Christopher E. Jensen
PRINCIPAL_INVESTIGATOR
Site Public Contact
Andrea Sitlinger
PRINCIPAL_INVESTIGATOR
Site Public Contact
Michael Wysota
PRINCIPAL_INVESTIGATOR
Site Public Contact
Boyu Hu
PRINCIPAL_INVESTIGATOR
Site Public Contact
Victor Y. Yazbeck
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Jason Comer
PRINCIPAL_INVESTIGATOR
Site Public Contact
Vikram Raghunathan
PRINCIPAL_INVESTIGATOR
Site Public Contact
Mazyar Shadman
PRINCIPAL_INVESTIGATOR
Site Public Contact
Paul S. Martin
PRINCIPAL_INVESTIGATOR
Site Public Contact
Gulrayz Ahmed
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Timothy R. Wassenaar
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.